Erectile Dysfunction and Platelet-rich plasma (PRP): what the trial registry contains
The ClinicalTrials.gov registry holds 22 records for PRP in Erectile Dysfunction: 1 recruiting now, 6 labelled Phase 3 or 4, across 11 countries. Snapshot 2026-08-29.
Why this is studied in Erectile Dysfunction
Erectile dysfunction is usually vascular and endothelial rather than structural, which is why regenerative approaches — cells, exosomes and shockwave adjuncts — target penile blood flow and nerve recovery. Post-prostatectomy nerve injury is a separate problem with a different time course, and the two are frequently blurred together in marketing.
What PRP means in this table
Platelet-rich plasma is a blood product, not a stem-cell product, though it is routinely sold as part of the same package. Preparation varies enormously between systems — platelet concentration, leukocyte content and activation all differ — so the label describes a category of procedure rather than a defined substance, which is the main reason its trial literature is so inconsistent.
The numbers
Every figure below comes from one reproducible query (erectile dysfunction x platelet-rich plasma) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 22 |
| Interventional studies in the sample | 22 |
| Recruiting right now | 1 |
| Completed | 6 |
| Terminated, withdrawn or suspended | 3 |
| Phase 3 or Phase 4 records | 6 |
| Countries with at least one site | 11 |
| Median planned enrolment | 60 participants |
| Largest single planned enrolment | 160 participants |
| First / most recent start year | 2019 — 2026 |
How mature is this evidence?
Later-phase work exists but is not dominant (6 of 22), which is the typical profile of a field that has shown safety and is still testing whether benefit survives a control arm.
Completion status: 6 completed, 3 stopped early (14% of all records). A registration is a plan, not a result.
| Phase label | Records | Share |
|---|---|---|
| Phase 2 | 10 | 36% |
| Not applicable | 6 | 21% |
| Phase 1 | 6 | 21% |
| Phase 3 | 5 | 18% |
| Phase 4 | 1 | 4% |
Median planned enrolment is 60 participants (largest single study: 160). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Country coverage runs to 11, but the distribution has a long tail behind United States at about 25% of mentions.
| Country | Studies with a site there |
|---|---|
| United States | 5 |
| Egypt | 4 |
| Taiwan | 2 |
| Spain | 2 |
| Greece | 2 |
| Kazakhstan | 1 |
| Italy | 1 |
| Lebanon | 1 |
| China | 1 |
| Turkey (Türkiye) | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Sponsorship leans academic: 11 of the most frequent lead sponsors read as academic or hospital entities and 0 as companies. Who pays shapes what gets measured and what gets published.
- University of Miami — 3 records
- Institute for the Study of Urological Diseases, Greece — 3 records
- Benha University — 2 records
- Mansoura University — 1 record
- National Scientific Medical Center, Kazakhstan — 1 record
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07124871 — PRP Exosomes Therapy for Erectile Dysfunction | Phase 2 | Recruiting | 30 | Institute for the Study of Urological Diseases, Greece | 2025-06-20 |
| NCT06942988 — Efficacy of Intracavernous Platelet-rich Plasma Injection in the Treatment of Erectile Dysfunction | Phase 3 | Active Not Recruiting | 34 | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | 2023-12-29 |
| NCT07544537 — A Prospective Comparative Study of Autologous Bone Marrow-Derived and Adipose Tissue-Derived Mesenchymal Stem Cells Versus Platelet-Rich Plasma and St | Phase 2 | Active Not Recruiting | 100 | National Scientific Medical Center, Kazakhstan | 2024-09-09 |
| NCT06433596 — Autologous PRP and Focal Shock Waves for Erectile Dysfunction | n/a | Active Not Recruiting | 116 | Elexial Research Limited | 2024-05-06 |
| NCT07602608 — Platelet-Rich Plasma With or Without Tadalafil for Erectile Dysfunction | Phase 4 | Completed | 160 | Benha University | 2025-04-15 |
| NCT07761806 — Comparsion of Effect of PRP,PDE5 Inhibitor in Treatment of Erectile Dysfunction | Phase 2, Phase 3 | Completed | 75 | Ain Shams University | 2024-01-15 |
| NCT05366504 — LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment | Phase 2, Phase 3 | Unknown | 60 | Institute for the Study of Urological Diseases, Greece | 2022-09 |
| NCT04357353 — The Role of Platelet Rich Plasma for Erectile Dysfunction | Phase 3 | Terminated | 13 | University of Nebraska | 2021-04-01 |
| NCT04050020 — Platelet-rich Plasma (PRP) Injection for Treatment of Erectile Function | Phase 2, Phase 3 | Completed | 60 | Institute for the Study of Urological Diseases, Greece | 2019-09-02 |
| NCT06550752 — Erectile Dysfunction Treatment Using Stem Cells | Phase 1, Phase 2 | Not Yet Recruiting | 30 | COR clinic of Regenerative Medicine | 2024-08-10 |
What this page does and does not tell you
These figures describe effort, not outcome. Published results, with their control arms and endpoints, are where benefit is decided.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many PRP studies for Erectile Dysfunction are recruiting right now?
1 of 22 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is PRP an approved treatment for Erectile Dysfunction?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 22 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on PRP for Erectile Dysfunction?
6 of 22 records carry a Phase 3 or Phase 4 label and 6 are marked completed. Registrations run from 2019 to 2026.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Erectile Dysfunction: cell-therapy evidence and registered trials
- How much does stem cell therapy for Erectile Dysfunction cost? (2026)
- Erectile Dysfunction stem cell therapy — your questions answered (2026)
- Erectile Dysfunction: cell-therapy evidence by therapy class
- MSC vs PRP for Erectile Dysfunction: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.